Why Investors Need to Take Advantage of These 2 Finance Stocks Now

Zacks identifies Arch Capital Group (ACGL) and MetLife (MET) as potential earnings-surprise candidates, not as companies that have already reported results. ACGL has a +11.70% Earnings ESP, based on a $2.29 most accurate EPS estimate versus a $2.05 consensus, and a Zacks #3 (Hold) rating; its report is scheduled for October 27, 2026. MET has a +1.41% ESP ($2.73 estimate versus $2.69 consensus), a #2 (Buy) rating, and is scheduled to report November 4, 2026; Zacks says its positive-ESP, #3-or-better screen produced positive EPS surprises 70% of the time in its backtest.

Analysis

The ESP figures are revision signals, not evidence of improving underlying earnings power. The larger ACGL gap is potentially more informative than MET’s, but it may also reflect a single or stale estimate; the article gives no revision breadth, estimate history, or independent validation. For ACGL, the key read-through is not just EPS versus consensus: catastrophe losses, reserve development, and renewal pricing can make a headline beat low-quality or non-repeatable. For MET, investment income and credit/market-sensitive items may drive reported EPS without establishing a durable change in core spread economics. In both cases, a beat can fail to lift shares if guidance or earnings quality disappoints.

Near term, event volatility dominates. Do not infer attractive upside from the cited historical backtest: the article provides no details on costs, drawdowns, selection effects, or whether returns were risk-adjusted. Over 1–3 months, the differentiator is whether results and management commentary confirm the estimate revisions; over 6–18 months, ACGL’s underwriting/pricing cycle and MET’s rate, credit, and investment portfolio exposures matter more than one quarter’s surprise. The contrarian risk is that investors trade the beat probability while overlooking the possibility that expectations are already reflected in prices. No valuation, implied-move, or consensus-revision data are supplied, so avoid an unhedged pre-earnings directional bet.

Key Decisions for Investors

• Treat ACGL as the higher-priority earnings watch, not an automatic buy. Before the October 27 report, verify how many analysts revised estimates, when they revised, and whether the change reflects recurring underwriting results rather than volatile catastrophe or reserve items.
• For MET ahead of November 4, stay neutral absent confirmation that estimate revisions map to core earnings. Review investment income, credit-related commentary, and guidance alongside the EPS print.
• If taking event exposure, wait for results and consider entering only after the initial reaction if the beat is accompanied by supportive guidance and earnings quality. Check options-implied moves first; without that and current prices, no risk/reward edge is established.
• Falsify the positive setup if either company reports below the cited consensus ($2.05 ACGL; $2.69 MET), or beats but signals weaker forward fundamentals. Reassess if updated estimates reverse before the releases.